Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 11, 2004, Pages 1388-1391

  Eyob, G ^a   Guebrexabher, H ^b   Lemma, E ^a   Wolday, D ^c   Gebeyehu, M ^a   Abated, G ^b   Rigouts, L ^d   Van Soolingen, D ^e   Fontanet, A ^f   Sanders, E ^c   Dorigo Zetsma, J W ^c,g  

^a ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^b ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^c Ethio Netherlands AIDS Research Project ENARP   (Ethiopia)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f INSTITUT PASTEUR   (France)

^g C/O M Oud   (Netherlands)

Author keywords

Drug resistance; Ethiopia; HIV 1; Long term follow up; Tuberculosis

Indexed keywords

ADULT; ARTICLE; EARLY DIAGNOSIS; ETHIOPIA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS CELL INTERACTION;

ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; ETHIOPIA; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 10044250164     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Espinal M A, Simonsen L, Laszlo A. Anti-tuberculosis drug resistance in the world. Report 2. Geneva, Switzerland: World Health Organization, 2000: p 253
2. Demissie M, Gebeyehu M, Berhane Y. Primary resistance to anti-tuberculosis drugs in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis 1997; 1: 64-67.
3. Demissie M, Lemma E, Gebeyehu M, Lindtjorn B. Sensitivity to anti-tuberculosis drugs in HIV-positive and -negative patients in Addis Ababa. Scand J Infect Dis 2001; 33: 914-919.
4. Abate G. Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendations. Ethiop Med J 2002; 40: 79-86.
5. Bruchfeld J, Aderaye G, Palme I B, et al. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection. J Clin Microbiol 2002; 40: 1636-1643.
6. Canetti G, Fox W, Khomenko A G, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ 1969; 41: 21-43.
7. Morcillo N, Zumarraga M, Alito A, et al. A low-cost, home-made, reverse-line blot hybridisation assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2002; 6: 959-965.
8. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
9. Noeske J, Nguenko P N. Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens. Trans R Soc Trop Med Hyg 2002; 96: 429-433.
10. Davies G R, Connolly C, Sturm A W, McAdam K P, Wilkinson D. Twice-weekly, directly observed treatment for HIV-infected and -uninfected tuberculosis patients: cohort study in rural South Africa. AIDS 1999; 13: 811-817.
11. Spellman C W, Matty K J, Weis S E. A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. AIDS 1998; 12: 191-195.
12. Murray J, Sonnenberg P, Shearer S C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740.
13. Shafer R W, Bloch A W, Larkin C, et al. Predictors of survival in HIV-infected tuberculosis patients. AIDS 1996; 10: 69-72.